SAF, The discussions today have morphed a bit o

SAF,

The discussions today have morphed a bit over multiple replies.

I hope to respond appropriately.

I, as most, am concerned that “performance bonuses” are tied to objective performance metrics that advance both the company and shareholders interests, not solely the executives of Cytodyn.

With that being said, irrespective of Dr. Pourhassan’s deference to the FDA, I do not believe that EUA and approval processes, especially in the Covid arena, are either transparent or consistent. I hope that this is not the case with the MHRA.

I hesitate to judge Pourhassan et al solely on short-term regulatory outcomes, as the processes seems at times unfair. I believe we are in agreement on that.

Nonetheless, executives are hired for their ability to execute, not explain failures.

As it appears by the reported forfeiture by Dr. Pourhassan of a 6M share bonus for failure to achieve a performance goal, the bar is not being set so low that stumbling along is generously rewarded.

I hope that we will continue to support the Cytodyn management as it continues to EUA/approval. We don’t know what is coming next, and neither do they (witness Covid for an HIV drug company).

I remain supportive as long as the company actions are appropriate, even if unexpected.

Thanks for your continued valuable discourse.

Be well